Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 197.01

-2.9%

Dec 1 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (27413)	1/15/1999 10:57:00 AM
From: Henry Niman	Read Replies (1) of 32384

V1, The most extensive preclinical work published was on animal models of breast cancer and diabetes, and Targretin produced impressive results for both diseases (see post #0 on this thread). Targretin showed efficacy for treating and preventing both conditions as well as synergizing with current approved products for treating humans (Tamoxifen for breast cancer and Rezulin for diabetes). In addition, Targretin synergized with a second generation compound for diabetes (SBH's Avandia) as did LGND's second generation rexinoid, LGD1268.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next